

François Maltais

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5654661/publications.pdf>

Version: 2024-02-01

56
papers

7,320
citations

218592

26
h-index

168321

53
g-index

56
all docs

56
docs citations

56
times ranked

5907
citing authors

#	ARTICLE	IF	CITATIONS
1	An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, e13-e64.	2.5	2,668
2	American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1390-1413.	2.5	1,644
3	Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease – 2007 Update. <i>Canadian Respiratory Journal</i> , 2007, 14, 5B-32B.	0.8	415
4	Effects of Home-Based Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2008, 149, 869.	2.0	323
5	Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. <i>European Respiratory Journal</i> , 2016, 47, 429-460.	3.1	311
6	Improvements in Symptom-Limited Exercise Performance Over 8 h With Once-Daily Tiotropium in Patients With COPD. <i>Chest</i> , 2005, 128, 1168-1178.	0.4	291
7	Decline of Resting Inspiratory Capacity in COPD. <i>Chest</i> , 2012, 141, 753-762.	0.4	150
8	The Metabolic Syndrome in Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2005, 25, 226-232.	0.5	144
9	Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 125-132.	0.7	122
10	Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 285-298.	2.5	110
11	Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. <i>Respiratory Medicine</i> , 2011, 105, 580-587.	1.3	96
12	Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. <i>Respiratory Research</i> , 2019, 20, 238.	1.4	81
13	The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD. <i>BMC Pulmonary Medicine</i> , 2010, 10, 55.	0.8	71
14	Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. <i>Therapeutic Advances in Respiratory Disease</i> , 2014, 8, 169-181.	1.0	65
15	Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. <i>European Respiratory Journal</i> , 2017, 49, 1601348.	3.1	64
16	Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0166745.	1.1	63
17	Responsiveness of Various Exercise-Testing Protocols to Therapeutic Interventions in COPD. <i>Pulmonary Medicine</i> , 2013, 2013, 1-11.	0.5	56
18	Functional Tests in Chronic Obstructive Pulmonary Disease, Part 1: Clinical Relevance and Links to the International Classification of Functioning, Disability, and Health. <i>Annals of the American Thoracic Society</i> , 2017, 14, 778-784.	1.5	52

#	ARTICLE	IF	CITATIONS
19	Fatigue in COPD: Prevalence and effect on outcomes in pulmonary rehabilitation. <i>Chronic Respiratory Disease</i> , 2011, 8, 119-128.	1.0	46
20	Update on Asthmaâ€“COPD Overlap (ACO): A Narrative Review. <i>International Journal of COPD</i> , 2021, Volume 16, 1783-1799.	0.9	46
21	Identification and definition of asthmaâ€“COPD overlap: The CanCOLD study. <i>Respirology</i> , 2020, 25, 836-849.	1.3	45
22	Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD â€“ 2019 update of evidence. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2019, 3, 210-232.	0.2	43
23	Paced-Walk and Step Tests to Assess Exertional Dyspnea in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009, 6, 330-339.	0.7	33
24	Ectopic fat accumulation in patients with COPD: an ECLIPSE substudy. <i>International Journal of COPD</i> , 2017, Volume 12, 451-460.	0.9	33
25	Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness <i>versus</i> tiotropium alone in COPD. <i>European Respiratory Journal</i> , 2019, 53, 1802049.	3.1	30
26	Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346581875509.	1.0	29
27	Ambient Air Pollution and Dysanapsis: Associations with Lung Function and Chronic Obstructive Pulmonary Disease in the Canadian Cohort Obstructive Lung Disease Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 44-55.	2.5	24
28	Quality Assurance of Spirometry in a Population-Based Study â€“Predictors of Good Outcome in Spirometry Testing. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 143-151.	0.7	23
29	Inter-day testâ€“retest reliability and feasibility of isokinetic, isometric, and isotonic measurements to assess quadriceps endurance in people with chronic obstructive pulmonary disease: A multicenter study. <i>Chronic Respiratory Disease</i> , 2019, 16, 147997311881649.	1.0	22
30	Asthma-COPD Overlap Phenotypes and Smoking :Comparative features of asthma in smoking or non-smoking patients with an incomplete reversibility of airway obstruction. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018, 15, 130-138.	0.7	21
31	Impaired Ventilatory Efficiency, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease: Results from the CanCOLD Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1391-1402.	2.5	19
32	Detecting Improvements in Dyspnea in COPD Using a Three-Minute Constant Rate Shuttle Walking Protocol. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 395-400.	0.7	18
33	Physical Frailty in COPD Patients with Chronic Respiratory Failure. <i>International Journal of COPD</i> , 2021, Volume 16, 1381-1392.	0.9	18
34	Ectopic adiposity and cardiometabolic health in COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 3331-3340.	0.9	16
35	The Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and the Heterogeneity of Risk Factors in the Canadian Population: Results from the Canadian Obstructive Lung Disease (COLD) Study. <i>International Journal of COPD</i> , 2021, Volume 16, 305-320.	0.9	16
36	Lung cancer resection and postoperative outcomes in COPD: A single-center experience. <i>Chronic Respiratory Disease</i> , 2020, 17, 147997312092543.	1.0	14

#	ARTICLE	IF	CITATIONS
37	Prospective validation of the endurance shuttle walking test in the context of bronchodilation in COPD. <i>European Respiratory Journal</i> , 2014, 44, 1166-1176.	3.1	13
38	Exploring PI3K Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials. <i>International Journal of COPD</i> , 2021, Volume 16, 1621-1636.	0.9	13
39	Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement. <i>International Journal of COPD</i> , 2021, Volume 16, 1215-1226.	0.9	8
40	Long-Term Effectiveness of a Home-Based Pulmonary Rehabilitation in Older People with Chronic Obstructive Pulmonary Disease: A Retrospective Study. <i>International Journal of COPD</i> , 2020, Volume 15, 2505-2514.	0.9	7
41	Home-based Pulmonary Rehabilitation is Effective in Frail COPD Patients with Chronic Respiratory Failure. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2022, 9, 15-25.	0.5	7
42	Physical and affective components of dyspnoea are improved by pulmonary rehabilitation in COPD. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001160.	1.2	7
43	Longitudinal comparison of outcomes in patients with smoking-related asthma-COPD overlap and in non-smoking asthmatics with incomplete reversibility of airway obstruction. <i>International Journal of COPD</i> , 2019, Volume 14, 493-498.	0.9	6
44	Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial. <i>International Journal of COPD</i> , 2021, Volume 16, 1939-1956.	0.9	6
45	Cardiovascular Risk in COPD. <i>Chest</i> , 2020, 157, 753-754.	0.4	5
46	Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium versus tiotropium: the RED trial. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662093950.	1.0	4
47	Comparative measurement properties of constant work rate cycling and the endurance shuttle walking test in COPD: the TORRACTO clinical trial. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662092685.	1.0	4
48	Metabolic profiles among COPD and controls in the CanCOLD population-based cohort. <i>PLoS ONE</i> , 2020, 15, e0231072.	1.1	4
49	Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. <i>Advances in Therapy</i> , 2021, 38, 4815-4835.	1.3	4
50	Significance of <i>Stenotrophomonas maltophilia</i> When Detected in Sputum of Ambulatory Patients with COPD. <i>International Journal of COPD</i> , 2021, Volume 16, 2895-2900.	0.9	4
51	Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662096514.	1.0	2
52	Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis. <i>International Journal of COPD</i> , 2019, Volume 14, 3053-3061.	0.9	2
53	Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. <i>International Journal of COPD</i> , 2021, Volume 16, 3105-3118.	0.9	2
54	Common pathophysiological pathways of the autonomic nervous system. , 2020, , 12-30.		0

#	ARTICLE	IF	CITATIONS
55	The Null Q0_{Our} Variant within a Copy-Neutral Loss-of-Heterozygosity Event Causing Alpha-1 Antitrypsin Deficiency. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 700-702.	1.4	0
56	Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD. Respiratory Medicine, 2022, , 106918.	1.3	0